生命科学工具供应商丹纳赫（DHR）今日盘中股价大幅下挫5.05%，引发市场关注。
消息面上，公司发布了最新财报及业绩展望。尽管其第四季度利润和收入超出市场预期，但公司对2026财年的利润预测与华尔街分析师的预期基本一致，并未带来惊喜，这可能是导致股价承压的主要原因。此外，公司首席执行官指出，全球学术与研究领域的需求持续疲软，特别是在美国和中国两大关键市场，这引发了投资者对公司未来增长动能的担忧。
根据公司展望，丹纳赫预计2026年调整后每股收益在8.35美元至8.50美元之间，与分析师的预期中值8.42美元相符。同时，公司预计2026年第一季度非GAAP核心营收将仅实现低个位数的同比增长。尽管公司在生物加工、诊断和生命科学业务方面显示出增长势头，并且中国诊断业务下滑幅度收窄，但整体增长指引未能激发市场更高的乐观情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.